ProCE Banner Activity

Enhancing Care in Moderate to Severe Psoriasis: Treatment Selection, Medication Adherence, and Healthcare Disparities

Slideset Download

Download these slides for an expert review of novel therapies, improved adherence, and reducing health disparities in the management of moderate to severe psoriasis

Released: September 09, 2022

Expiration: September 08, 2023

No longer available for credit.



Steven Feldman

Steven Feldman, MD, PhD

Professor of Dermatology, Pathology and Social Sciences & Health Policy
Wake Forest University School of Medicine
Winston-Salem, North Carolina

Melodie S. Young

Melodie S. Young, MSN, RN, ANP-C

Nurse Practitioner
Mindful Dermatology and Modern Research Associates
Dallas, Texas

Provided by

ProCE Banner
ProCE Banner


Supported by an educational grant from Novartis Pharmaceuticals Corporation.

Novartis Pharmaceuticals Corporation


Steven Feldman, MD, PhD: consultant/speaker: AbbVie, Accordant, Almirall, Alvotech, Amgen, Arcutis, Arena, Argenx, Biocon, Boehringer Ingelheim, Bristol-Myers Squibb, Dermavant, Forte, Helsinn, Janssen, Leo, Lilly, Mylan, Novartis, Pfizer, Samsung, Sanofi, Sun, UCB, vTv Therapeutics, Voluntis; researcher: Galderma, Janssen, Lilly, Pfizer, Regeneron; stock/stock options: Sensal Health.

Melodie S. Young, MSN, RN, ANP-C: consultant/advisor/speaker: AbbVie, Amgen, Arcutis, Boehringer Ingelheim, Janssen, Leo, Lilly, Novartis, UCB.

Additional Information

Program Medium

This program has been made available online.